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Background: The aims of this study were to evaluate the current awareness of and implementation by pharmacists
in Japan of adjustment of drug dosage according to renal function (ADDR) in patients with chronic kidney disease
(CKD) and to clarify the factors influencing implementation of ADDR by community pharmacists.
Methods: We conducted a web-based questionnaire of Japanese community and hospital pharmacists. Responders
were compared by characteristics, rate of implementation of ADDR, experience with adverse drug events, pharmacist
awareness of implementation of ADDR, and obstacles to ADDR implementation experienced by pharmacists.
Additionally, the factors influencing the implementation of ADDR by community pharmacists were investigated
by logistic regression analysis.
Results: Fewer community pharmacists had implemented ADDR than hospital pharmacists. The community
pharmacists had less experience with adverse drug events caused by an inappropriate dosage than the hospital
pharmacists, while the hospital pharmacists had encountered more severe adverse drug events than the
community pharmacists. The community pharmacists had less awareness of ADDR implementation, and
believed that problems in implementing ADDR were caused by a lack of information on the renal function of
patients. In the logistic regression analysis, the factors influencing implementation of ADDR were “Routinely
receiving prescriptions from nephrologists”, “Experience with adverse drug events caused by inappropriate
dosage for CKD patients”, and “Awareness of the need for pharmacists to check the dosage of renally excreted
drugs”; they did not include “Lack of information on patient renal function”.
Conclusions: This study indicates that fewer Japanese community pharmacists than hospital pharmacists
implement ADDR and that implementation of ADDR by community pharmacists is hindered by their limited
awareness of the importance of patient renal function. We advocate that many countermeasures be introduced
to prevent CKD patients from experiencing adverse drug events caused by inappropriate dosage. Such
countermeasures would include a training program to educate pharmacists about the impact of impaired renal
function on dosage of drugs that are excreted by the kidneys.
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Chronic kidney disease (CKD) is, an important and com-
mon health problem. Its incidence and prevalence are
increasing worldwide. The estimated overall prevalence
of CKD (glomerular filtration rate <60 mL/min/1.73 m2)
in adults (aged ≥18) is increasing exponentially in the
older population in Japan [1]. Pharmacokinetics are
often altered in CKD patients [2]. In particular, the op-
timal dosages of renally excreted drugs are strongly af-
fected by renal impairment. Dosages that do not take
renal function into account are a major cause of increases
in drug blood concentrations that lead to adverse drug
events [3,4]. Appropriate dosages of renally excreted drugs
can be calculated on the basis of renal function using cre-
atinine clearance. Thus, dosage adjustment based on renal
function contributes to a reduction in the incidence of ad-
verse drug events in older patients and others with renal
impairment [5-7].
Adjustment of the drug dosage according to renal
function (ADDR) by pharmacists, as a result of checking
renal function and recommending alterations in their
prescriptions, can prevent inappropriate dosages and
thus reduce the incidence of the resulting adverse drug
events [8,9]. Hassan et al. [6] reported that hospital
pharmacists can contribute to a reduction in the inci-
dence of adverse drug events in patients with renal im-
pairment. Conversely, the contribution of community
pharmacists to ADDR seems limited in Japan [10] and in
other countries [11]. Although hospital pharmacists can
easily obtain information on patient renal function from
medical records, community pharmacists may find it dif-
ficult. We might expect that the limited contribution to
the implementation of ADDR by community pharmacists
might be because of the unavailability of information on
patient renal function in community pharmacies. How-
ever, the practical reasons remain unclear. We conductedTable 1 Questionnaire on pharmacotherapy for CKD patients
Information requested Information obtain
Type of work Community pharma
Geographical distribution Prefecture
Work experience (years) <5, 5–9, 10–20, >20






Awareness of pharmacotherapy of CKD patients Four items, using a
Experience with adverse drug events caused by
inappropriate dosage for CKD patients
Yes/No; when “yes”
drug event
Implementation of ADDR Implemented/not im
Obstacles to implementation of ADDR for CKD
patients
Multiple choice forma questionnaire-based survey to evaluate the current
awareness of community pharmacists of ADDR for CKD
patients in Japan and to compare the responses of com-
munity pharmacists with those of hospital pharmacists.
Additionally, to clarify why community pharmacists are




A web-based survey was developed to investigate various
factors relating to the pharmacotherapy of CKD patients.
A web-based questionnaire has advantages that include
access to individuals in distant locations, the ability to
reach difficult-to-contact participants, and the conveni-
ence of having automated data collection, which reduces
researcher time and effort [12]. The survey was conducted
via the Internet using “Google Forms”, a questionnaire-
style information-collecting system for efficiently adminis-
tering questionnaires [13]. The items in the survey are
listed in Table 1. Pharmacists were invited to participate
via the relevant pharmacist association’s mailing lists in
each geographical area and via pharmacists’ groups on so-
cial networking sites. Because the URL of the survey web-
site consisted of a random character string, general surfers
of the Internet could not access the site. The timeframe
for responding was 1 month (from May 1st to 31st, 2013).
We did not send any reminders. The survey data were
compared with Japanese national statistics on pharma-
cists from the Survey of Physicians, Dentists and Phar-
macists 2012 by the Ministry of Health, Labour and
Welfare [14]. We had estimated the percentage of
pharmacists with <5 years working experience by the
age distribution from the national statistics. The Ethics
Committee of Kumamoto University approved the study
(no. 788).ed
cist/Hospital pharmacist
at/17 departments (general internal medicine, respiratory medicine,
phrology, endocrinology, hematology, psychiatry, pediatrics, orthopedics,
almology, urology, surgery, otorhinolaryngology, dentistry, obstetrics and
5-point Likert-type scale
selected, respondent asked to name the drug that caused the adverse
plemented
at/five possible obstacles listed
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All statistical analyses were performed with EZR (Saitama
Medical Center, Jichi Medical University, Japan), which is
a graphical user interface for R [15] (The R Foundation
for Statistical Computing, Vienna, Austria). More pre-
cisely, EZR is a modified version of R Commander de-
signed to add statistical functions frequently used in
biostatistics [16]. Univariate analyses to compare com-
munity and hospital pharmacists were performed using
the chi-square or Mann–Whitney U tests. Logistic re-
gression analysis was used to identify the factors in-
fluencing implementation of ADDR by community
pharmacists. Logistic regression was performed using
stepwise model selection according to the Akaike in-
formation criterion [17]. Significance values were set
at p <0.05 for interpreting the final multivariate logis-
tic regression model.
Results
Relevant characteristics of responders
Relevant characteristics of responders are shown in Table 2.
Two hundred eighty-four pharmacists responded to the
survey, including 190 community pharmacists (66.9%) and
94 hospital pharmacists (33.1%). Forty-five (15.8%), 73
(25.7%), 101 (35.6%), and 65 (22.9%) pharmacists had
worked for <5, 5–9, 10–20, and >20 years, respectively.
The community pharmacists routinely dispensed prescrip-
tions for a median of three hospital departments. Eighty
pharmacists (39.2%) routinely dispensed prescriptions from
nephrologists. The community pharmacists routinely
dispensed prescriptions from significantly fewer depart-
ments and dispensed significantly fewer prescriptions
from nephrologists than the hospital pharmacists. The
responding pharmacists were distributed throughout
Japan (40/47 prefectures). The ratios of community to
hospital pharmacists in the national statistics and in our
data set were 2.5:1 and 3:1, respectively. The estimated
percentage of pharmacists with <5 years of workingTable 2 Characteristics of responders
Characteristic Total C
Work experience, n (%)
<5 years 45 (15.8) 2
5–9 years 73 (25.7) 5
10–20 years 101 (35.6) 7
>20 years 65 (22.9) 4
Number of departments for which prescriptions
routinely dispensed, median (IQR)
3 (5) 3




bMann–Whitney test.experience in the national statistics was approximately
15.4%; the percentage with <5 years working experi-
ence in our dataset was similar (15.8%).Implementation of ADDR for CKD patients in Japan
We investigated the implementation of ADDR for CKD
patients in Japan. Most hospital pharmacists (n = 86,
91.5%) implemented ADDR. In contrast, only about
half of the community pharmacists (n = 103, 54.2%)
had implemented ADDR (Table 3).Experience with adverse drug events caused by
inappropriate dosage for CKD patients
We investigated the pharmacists’ experience with ad-
verse drug events caused by an inappropriate dosage for
CKD patients. As shown in Table 3, significantly fewer
community pharmacists (n = 22, 11.6%) than hospital
pharmacists (n = 47, 50.0%) had experienced such ad-
verse drug events. We also investigated which drugs had
caused these adverse drug events. The drugs most fre-
quently cited by hospital and community pharmacists
were antivirals and pregabalin, respectively. We also
identified other differences between community and
hospital pharmacists in terms of their experience with
such adverse drug events (Figure 1).Awareness of pharmacotherapy for CKD patients
We examined the participating pharmacists’ awareness of
pharmacotherapy for CKD patients. Significantly fewer
community pharmacists than hospital pharmacists were
aware of the need for “Checking of dosage of renally ex-
creted drugs”, “Recommending dosage of renally excreted
drugs to doctors”, and “Monitoring of drug-induced renal
dysfunction” (Median Likert scale (IQR) = 4 (1) to 5
(0), 4 (1) to 5 (1), and 4 (1) to 5 (1)). The score distri-
butions are shown in Figure 2.ommunity pharmacists Hospital pharmacists p value
0.63a
7 (14.2) 18 (19.1)
0 (26.3) 23 (24.5)
1 (37.4) 30 (31.9)
2 (22.1) 23 (24.4)
(5) 4 (9) <0.001b
3 (17.6) 47 (50.0) <0.001b
Table 3 Rate of implementation of ADDR and experience with adverse drug events caused by inappropriate dosage for
CKD patients
Questionnaire items Community pharmacists n (%) Hospital pharmacists n (%) p value
Implementation of ADDR <0.001a
Implemented 103 (54.2) 86 (91.5)
Not implemented 87 (45.8) 8 (8.5)
Experience with adverse drug events caused by
inappropriate dosage for patient with CKD
<0.001a
Yes 22 (11.6) 47 (50)
No 168 (88.4) 47 (50)
aChi-square test.
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pharmacists
As shown in Table 4, more community pharmacists
(n = 168, 88.4%) than hospital pharmacists (n = 13, 13.8%)
responded that “Difficulty in obtaining information on pa-
tient renal function” was an obstacle to implementation of
ADDR.Factors influencing implementation of ADDR for CKD
patients by community pharmacists
The final model of the logistic regression identified that the
factors influencing implementation of ADDR by commu-
nity pharmacists were “Routinely receiving prescriptions
from nephrologists” (OR: 3.12, CI: 1.16–8.44), “Experience
with adverse drug events caused by inappropriate dosage
for CKD patients” (OR: 3.92, CI: 1.00–15.3), and “Aware-
ness of need for pharmacists to check dosage of renally























Figure 1 Renally-excreted drugs cited by pharmacists as having causeDiscussion
We demonstrated that community pharmacists had less
awareness of and less frequently implemented ADDR for
CKD patients than did hospital pharmacists. The less fre-
quent implementation of ADDR by community pharma-
cists was attributable to differences in “Awareness of need
for pharmacists to check dosage of renally excreted
drugs”, “Routinely dispensing prescriptions from ne-
phrologists”, and “Experience with adverse drug events
caused by inappropriate dosage for CKD patients”.
Prescription errors, including inappropriate dosage for
CKD patients, are associated with adverse drug events
[18-21], and seem to be common. Via-Sosa et al. [11]
and Joosten et al. [22] reported that community pharma-
cists sometimes dispense inappropriate dosages for CKD
patients. In our study, half the participating community
pharmacists had never implemented ADDR, and fewer
community pharmacists than hospital pharmacists had
implemented ADDR (Table 3). These findings suggest6 8 10 12
st Community pharmacist
Number
d ADRs. aNSAIDs:Non-steroidal anti-Inflammatory drugs.
Checking of dosage of 
renally-excreted drugs by pharmacist 
Checking whether drugs that cause 
renal dysfunction have been 
prescribed for CKD patients
Recommending dosage of 
renally-excreted drugs to doctors 











Figure 2 Pharmacists’ awareness of pharmacotherapy for CKD in Japanese patients. The awareness score is the median score on the Likert
scale for each item.
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appropriate dosages of drugs to CKD patients. Health
care professionals’ awareness is influenced by their ex-
perience with clinical problems such as adverse drug
events. In turn, the awareness of health care profes-
sionals, including pharmacists, greatly influences their
behavior [23-25]. In our study, more hospital than
community pharmacists had experienced adverse drug
events (Table 3). Additionally, the hospital pharmacists
had experienced more severe adverse drug events such
as hospitalization and/or death than the community
pharmacists (e.g., neurotoxicity of antivirals [26], di-
goxin intoxication [27]) (Figure 1). Fewer community
pharmacists than hospital pharmacists were aware of
the need to check and recommend appropriate dosages
of renally excreted drugs and to monitor drug-induced
renal dysfunction (Figure 2). Furthermore, in this study,
pharmacists’ experience with adverse drug events was re-
lated to awareness of the need for checking and recom-
mending appropriate dosages (data not shown). These
findings suggest that hospital pharmacists have moreTable 4 Obstacles to ADDR implementation experienced by p
Characteristics Commu
Failure to check prescription because of pressure of other work 57 (30)
Difficulty in obtaining information on patient renal
function (e.g., serum creatinine)
168 (88.
Fear of doctor’s rejection 32 (16.8
Lack of pharmacists’ skill 109 (57.
Lack of relevant pharmaceutical information 61 (32.1
aChi-square test.experience with adverse drug events and that this re-
sults in them having more awareness of the need for
ADDR. Thus, hospital pharmacists are more careful
and are able to implement ADDR. In contrast, al-
though many community pharmacists responded that
checking the dosage was “important”, half of commu-
nity pharmacists had not implemented ADDR. We be-
lieve there is a considerable gap between “important”
and “very important”. Hence, we performed a subgroup
analysis of the community pharmacists to compare aware-
ness of the need for pharmacists to check dosage of
renally excreted drugs and implementation of ADDR.
Significantly more community pharmacists that had
implemented ADDR responded that checking the dosage
was “very important” rather than “important” (Additional
file 1: Table S1). These results suggest a need for greater
awareness among community pharmacists for implement-
ing ADDR.
Most community pharmacists indicated that the most
frequent obstacle to implementing ADDR was “Difficulty
in obtaining information on patient renal function” whereasharmacists
nity pharmacists n (%) Hospital pharmacists n (%) p value
53 (56.4) <0.001a
4) 13 (13.8) <0.001a
) 10 (10.6) 0.227a
4) 45 (47.9) 0.166a
) 42 (44.7) 0.052a









No (ref) 1.16–8.44 0.0247
Yes 3.12
Experience with adverse drug
events caused by inappropriate
dosage
No (ref) 1.00–15.3 0.0498
Yes 3.92
Work experience
<5 years (ref) 0.96–6.02 0.616
≥5 years 2.40
Awareness of need for pharmacists
to check dosage of renally excreted
drugs
4.44 2.52–7.81 <0.001
Predictors: duration of work experience, Routinely dispense prescriptions from
nephrologists, obstacle to implementation of ADDR, awareness of
pharmacotherapy for CKD patients.
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scriptions because of pressure of other work” (Table 4). In
Japan, community pharmacists generally do not have access
to patient medical records, unlike hospital pharmacists.
Thus, community pharmacists believe that their failure to
implement ADDR is caused by a lack of information on pa-
tient renal function. However, about half the community
pharmacists had implemented ADDR (Table 3). We there-
fore conclude that lack of information on renal function is
not a critical factor in the failure of community pharmacists
to implement ADDR.
To clarify the critical factors that influence implementa-
tion of ADDR by community pharmacists, we used logistic
regression analysis. The final model of the logistic regres-
sion indicated that the influential factors were “Routinely
dispensing prescriptions from nephrologists”, “Experience
with adverse drug events caused by inappropriate dosage”,
“Awareness of the need for pharmacists to check dosage of
renally excreted drugs” (Table 5). However, “Difficulty in
obtaining information about renal function” was not iden-
tified as a contributory factor. Additionally, in this study,
dispensing prescriptions from nephrologists (i.e., participa-
tion in pharmacotherapy of CKD) tended to be related to
awareness of the need for checking and recommending ap-
propriate dosages (data not shown). These results are con-
sistent with our argument that pharmacists’ experience
with adverse drug events with CKD patients make them
more likely to check prescriptions associated with ADDR
policy. In contrast, in the Netherlands, the serum creatin-
ine concentration is printed on prescriptions for designated
drugs including renally excreted drugs (e.g., acyclovir) [28].Recently, attempts to implement this policy have been
made more frequently in Japan. However, although the
serum creatinine concentration is generally an accurate in-
dicator of renal function, this measure is less reliable in
older people and those with malnutrition because of the
loss of muscle mass [29-31]. Renal impairment is fre-
quently overlooked in patients with such concealed renal
impairment (normal serum creatinine concentrations and
reduced estimated glomerular filtration rate), resulting in
the prescription of inappropriate dosages [32]. Wong et al.
[33] stressed that awareness that renal impairment can be
accompanied by normal serum creatinine concentrations is
important in preventing adverse drug events in older pa-
tients. These findings suggest that implementation of ADDR
by community pharmacists would be best supported by not
only providing information about serum creatinine concen-
trations, but also by the strategy of bringing renal impair-
ment to the attention of pharmacists when they check
prescriptions, by means, for example, of a computerized sys-
tem that alerts the pharmacist to renal impairment. Joosten
et al. [22] have demonstrated that a computer-based renal
impairment alert system is effective. However, it would be
difficult to introduce a computerized alert system for all
community pharmacists. Conversely, training programs for
physicians [7], medical staff [34], and community pharma-
cists [11] seem to reduce the percentage of inappropriate
dosage prescriptions. Thus, training programs to educate
community pharmacists on the risk of adverse drug events
caused by inappropriate dosages for CKD patients and en-
couraging them to pay attention to renal impairment may
be effective in increasing the rate of implementation of
ADDR.
This study has some limitations. Data validation in this
survey was not sufficient. Although we compared our
data with national statistics, this survey data lacks some
demographic characteristics of respondents, such as gen-
der, age, and qualifications of the pharmacist. Further-
more, the questionnaire invitation was sent via a closed
social network group and relevant pharmacist associa-
tions’ mailing lists. Because the exact number of invitees
was unknown, we were not able to calculate a response
rate and sample size. Additionally, this study has a sam-
pling bias, which is a disadvantage of the survey method.
A web-based questionnaire also has a self-selection/vol-
unteer bias [35]. This survey might have been biased to-
ward pharmacists who are concerned with or have an
interest in ADDR. Thus, this study might have overesti-
mated the percentage of pharmacists who have imple-
mented ADDR. Conversely, a web-based survey is easier
for participants to respond to because pharmacists who
have not implemented ADDR might feel stigmatized if
the survey were public [12]. Therefore, we chose the
web-based approach as a means of obtaining more re-
sponses from pharmacists in Japan. Although further
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ance of awareness among pharmacists in implementing
ADDR.
Conclusions
In summary, we have investigated the awareness and im-
plementation of ADDR for CKD patients by community
pharmacists. We found that community pharmacists
commonly adjust inappropriate dosages of drugs for
CKD patients. However, there is insufficient implementa-
tion of ADDR by community pharmacists and insufficient
awareness of the need for community pharmacists to check
prescriptions for patients with renal impairment and to im-
plement ADDR. We believe that immediate measures such
as training programs for community pharmacists are ne-
cessary to improve the current status of ADDR implemen-
tation in Japan by drawing their attention to the need to
check prescriptions for patients with renal impairment.
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